A Phase II Clinical Trial Evaluating the Preventive Effectiveness of Lactobacillus Vaginal Suppositories in Patients with Recurrent Cystitis by Wada, Koichiro et al.
A Phase II Clinical Trial Evaluating the Preventive Effectiveness 
of Lactobacillus Vaginal Suppositories in Patients with  
Recurrent Cystitis
Koichiro Wadaa＊,  Shinya Ueharab,  Ayano Ishiia,  Takuya Sadahiraa,   
Masumi Yamamotoa,  Ritsuko Mitsuhataa,  Atsushi Takamotoa,  Motoo Arakia,   
Yasuyuki Kobayashia,  Masami Watanabea,  Toyohiko Watanabea,   
Katsuyuki Hottac,  and Yasutomo Nasua
aDepartment of Urology,  Okayama University Graduate School of Medicine,  Dentistry and Pharmaceutical Sciences,   
and cCenter for innovative Clinical Medicine,  Okayama University Hospital,  Okayama 700-8558,  Japan,   
bDepartment of Urology,  Kawasaki Hospital,  Kawasaki Medical School,  Okayama 700-8505,  Japan
Urinary tract infections (UTIs) are the most common bacterial infections in women,  and many patients 
experience frequent recurrence.  The aim of this report is to introduce an on-going prospective phase 
II clinical trial performed to evaluate the preventive eﬀectiveness of Lactobacillus vaginal supposito-
ries for prevention of recurrent cystitis.  Patients enrolled in this study are administered vaginal sup-
positories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week 
for one year.  The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse 
events.  Recruitment began in December 2013 and target sample size is 20 participants.
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U rinary tract infections (UTIs) are the most com-mon bacterial infections in women.  Most cases 
of bacterial cystitis can be completely cured using 
antimicrobial agents recommended by the guidelines of 
the Japanese Association of Infectious Diseases (JAID) 
[1].  However,  many patients suﬀer from frequent 
recurrences of bacterial cystitis,  and most clinicians 
are faced with repeated and long-term administration 
of broad-spectrum antimicrobial agents.  Although 
urinary abnormalities or underlying urinary tract 
disease are not usually present,  the patientʼs quality 
of life is aﬀected and many women become frustrated 
by the repeated use of antimicrobial agents.  
Furthermore,  repeated and long-term antimicrobial 
use leads to the increased presence of drug-resistant 
bacteria and the disruption of normal levels of intesti-
nal and vaginal ﬂora [2].  Therefore,  a new strategy 
other than administration of antimicrobial prophylaxis 
against recurrent UTIs in women should be developed.
　 Reid et al.  reported several strategies for the 
prevention of recurrent UTIs.  These included the use 
of probiotics [3],  which are deﬁned as living microor-
ganisms that can be administered to promote the 
health of the host [4] by treating or preventing dis-
ease,  as an alternative preventative approach.  It has 
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been reported that the ﬂora of the urogenital tract in 
patients with recurrent UTIs is abnormal compared 
with those of healthy women [5-7].  This observation 
led to the investigation of the role of ﬂora,  particu-
larly lactobacilli,  in maintaining urogenital health and 
reducing the risk of infections.  The role of Lactoba­
cillus in the maintenance of vaginal health was ﬁrst 
recognized by Doederlein in the late 18th century [8].  
Vaginal lactobacilli protect the female urogenital tract 
from pathogen colonization and,  therefore,  can con-
tribute to the prevention of genitourinary tract infec-
tion.  Many studies have been published describing the 
relationships between bacterial vaginosis and lactoba-
cilli [9-11] and between lactobacilli and UTIs [3,  
12-14].  L. crispatus is readily isolated from the vaginas 
of healthy women [15,  16] and is nearly universal in 
its abilities to produce hydrogen peroxide,  which is 
toxic to many microorganisms in the vagina,  and bind 
to vaginal epithelial cells [17,  18].
　 While the eﬀectiveness of Lactobacillus vaginal sup-
positories against recurrent UTIs has been controver-
sial [19,  20],  the results of a 2006 clinical study at 
Okayama University Hospital published by Uehara et 
al.  [21] demonstrated the safety of Lactobacillus vagi-
nal suppositories and their eﬃcacy against recurrent 
cystitis.  The study was a prospective,  single-arm,  
pilot study,  in which Lactobacillus vaginal suppositories 
containing the GAI 98322 strain of Lactobacillus cris­
patus was used.  L. crispatus GAI 98322 was chosen due 
to its ability to produce more hydrogen peroxide than 
other strains of L. crispatus.  The 9 patients in the 2006 
study conducted at Okayama University Hospital 
demonstrated that vaginal suppositories containing 
L. crispatus could signiﬁcantly reduce UTI recurrence 
without complications during treatment.  Furthermore,  
Ann et al.  reported on a randomized control trial of 
L. crispatus vaginal suppositories,  with results sup-
porting their preventative eﬃcacy against recurrent 
urinary tract infections [22].
　 The present study is a larger phase II,  single-arm 
clinical trial to evaluate preventive eﬀectiveness and 
safety of Lactobacillus vaginal suppositories in patients 
with frequently recurrent cystitis.
Endpoints
　 The primary endpoint in this trial is recurrence of 
a cystitis which requires administration of antimicro-
bial agents.  Cystitis consists of pyuria,  bacteriuria 
and symptoms.  Pyuria is deﬁned as 10 white blood 
cells (WBCs)/µL as determined by ﬂow cytometric 
analysis; 10 WBCs/mm3 as counted using a count-
ing chamber or as indicated by a positive leucocyte 
esterase result using a urine test strip with uncentri-
fuged urine; or＞5 WBCs/high power ﬁeld (hpf) in 
the sediment of centrifuged urine.  Bacteriuria is 
deﬁned as catheter urine containing 104 CFU (col-
ony-forming units) /mL of live bacteria or midstream 
urine containing 105 CFU/mL.  Symptoms include 
micturition pain,  urinary frequency/urgency,  or lower 
abdominal pain.  Participants with asymptomatic pyuria 
and bacteriuria are not diagnosed as recurrent UTI.
　 During the administrations of antimicrobial agents 
against recurrent UTIs,  administration of vaginal 
suppositories should be continued for 1 year to count 
the number of recurrences.
　 Secondary endpoints are adverse events due to the 
suppository and changes in isolated vaginal bacterial 
strains monthly examined by culture of vaginal swabs.
Eligibility Criteria
　 Adult (less than 80 years old) female outpatients 
with 2 or more episodes of uncomplicated/compli-
cated cystitis within the past year can be enrolled.  
However,  the UTI must be treated and cured at entry.  
Complicated cystitis includes the crisis of chronic 
cystitis in patients performing clean intermittent self-
catheterization (CISC) and in patients with mild 
underlying diseases in their urinary tract such as 
overactive bladder (OAB) and neurogenic bladder 
(NGB) with 50ml or less of residual urine volume 
after urination.  Exclusion criteria include: the pres-
ence of underlying urological diseases for which a 
urological procedure is necessary; continuous urethral 
catheterization; uncontrollable and severe diseases 
such as diabetes mellitus (DM),  collagen diseases,  
advanced malignancies,  and heart/liver/kidney 
dysfunctions; allergy to dairy products or fermented 
dairy products; and low compliance,  as assessed by 
the investigators.
Treatment Methods
　 In this phase II study,  patients with acute uncom-
plicated/complicated cystitis will be recruited between 
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December 2013 and March 2018 at the Urology out-
patient clinic in Okayama University Hospital.
　 Lactobacillus strains. Lactobacillus crispatus 
GAI 98322 is used in this study because 1) it had 
already been isolated from the vaginas of healthy 
women and 2) a quantitative hydrogen peroxide assay 
performed in the pilot study determined that GAI 
98322 had the highest capacity for hydrogen peroxide 
production of 3 strains of L. crispatus (GAI 98322,  
GAI 99098,  and GAI 99099) provided by K.  Watanabe 
(Division of Anaerobe Research,  Life Science 
Research Center,  Gifu University,  Japan).
　 Vaginal suppositories. Lactobacillus vaginal 
suppositories containing L. crispatus GAI 98322 at 1.0
×108 CFU per suppository,  are made,  following a 
viability assay,  at the Pharmacy in Okayama 
University Hospital using the same method as Uehara 
et al.  [21].
　 Protocol. Patients without cystitis at entry into 
this trial are instructed to insert a vaginal suppository 
containing L. crispatus GAI 98332 every 2 days or 3 
times a week for 1 year before going to bed.  This 
regimen is used in the pilot study reported by Uehara 
et al.  [21].  The patients visit our hospital every month 
for an examination of subjective symptoms.  Urinalysis 
and culturing of urine and vaginal discharge are also 
performed.  UTI incidence and vaginal bacterial colo-
nization before and during administration of vaginal 
suppositories are compared.  If there is evidence of a 
recurrence of UTI as mentioned above,  an antimicro-
bial agent is simultaneously given with the vaginal 
suppository.
Statistical Consideration
　 In our outpatient clinic,  around 20 patients a year 
undergo treatment against uncomplicated/complicated 
cystitis via antimicrobial agents each year.  On aver-
age,  almost 50  of the patients,  especially with 
complicated cystitis,  experience recurrence of cysti-
tis.  We anticipate that 5 or 6 patients with consent 
will be enrolled in this study each year.  Thus,  a total 
of 20 patients will be included in this trial held within 
5 years.  The data is analyzed using JMP software 
(ver. 11; SAS,  Cary,  NC,  USA) and p＜0.05 is 
considered to be statistically signiﬁcant.  According to 
ﬁrst recurrence during the study,  mean and 50  
recurrence-free survival are evaluated by the Kaplan-
Meier method.  The data regarding to the number of 
recurrence during this study are analyzed using Mann-
Whitneyʼs exact test compared with those before 
administration of vaginal suppositories,  and the data 
of the number of recurrence are analyzed according to 
age,  menopausal or premenopausal,  kinds of patho-
gens and presence of underlying diseases in their uri-
nary tract (complicated or uncomplicated).  Furthermore,  
recurrence rate by deﬁnition of cystitis including 
pyuria,  bacteriuria and symptoms are evaluated using 
Chi-squared test.  Adverse events are assessed by 
Common Terminology Criteria for Adverse Events 
(CTCAE) ver. 4.0 and relationship between severity 
and administration duration is analyzed.
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